Doxycycline Hyclate Contract Award SPE2D2-25-D-0015
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The Defense Logistics Agency (DLA) Troop Support has issued an Award Notice for the Doxycycline Hyclate Contract (SPE2D2-25-D-0015). This notice specifically announces the execution of Option #1 for the period of July 2, 2026, through July 1, 2027. The original contract, valued at an estimated $6,425,267.05 over five years, was awarded to Puracap Laboratories for the supply of Doxycycline Hyclate 100 MG Tablets. All other terms and conditions remain unchanged.
Scope of Work
The contract covers the supply of Doxycycline Hyclate 100 MG Tablets in various unit counts (20, 30, 50, 100, 210, 300, 400, 500, and 1000). The place of manufacture/performance is Epic Pharma, located at 227-15 N. Conduit Avenue, Laurelton, NY 11413.
Contract & Timeline
- Type: Requirements-type contract (estimated)
- Duration: 5 years (estimated), with multiple option years
- Value: Estimated $6,425,267.05
- Set-Aside: Unrestricted
- Award Date: Puracap Laboratories' offer accepted after 06/20/2025 (Final Proposal Revisions)
- Latest Action: Option #1 executed on 06/09/2026 (published date of notice) for performance from 07/02/2026 to 07/01/2027.
Award Details
The contract was awarded to Puracap Laboratories following a solicitation (SPE2D2-25-R-0004). The acquisition was unrestricted, with a NAICS Code of 325412 and a size standard of 1300 employees. The original offer due date was 02/05/2025, with several amendments issued to correct information, extend the closing date, and allow email submissions. Final Proposal Revisions were opened on 06/20/2025, with no change in pricing from the initial offer.
Additional Notes
All other terms and conditions of the contract remain unchanged. The contract incorporates by reference FAR 52.212-1, 52.212-4, and 52.212-5.